Fargnoli Maria Concetta, Bardazzi Federico, Bianchi Luca, Dapavo Paolo, Fabbrocini Gabriella, Gisondi Paolo, Micali Giuseppe, Offidani Anna Maria, Pellacani Giovanni, Skroza Nevena, Angileri Rosa Giuseppa, Burlando Martina, Campanati Anna, Carrera Carlo Giovanni, Chiricozzi Andrea, Conti Andrea, Simone Clara De, Di Lernia Vito, Errichetti Enzo, Galluzzo Marco, Guarneri Claudio, Lasagni Claudia, Lembo Serena, Loconsole Francesco, Megna Matteo, Musumeci Maria Letizia, Prignano Francesca, Richetta Antonio Giovanni, Trovato Emanuele, Venturini Marina, Peris Ketty, Pinton Piergiacomo Calzavara
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Dermatology Unit, Ospedale San Salvatore, 67100 L'Aquila, Italy.
J Clin Med. 2023 May 18;12(10):3545. doi: 10.3390/jcm12103545.
Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = "strongly disagree" to 5 = "strongly agree") using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form "main principles" and 10 statements formed the final list. After a second round of voting, consensus was reached in 4/5 (80%) of the main principles and 8/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.
布罗达单抗是一种重组的、全人源免疫球蛋白IgG2单克隆抗体，特异性靶向白细胞介素-17受体A，已在欧洲获批用于治疗中重度银屑病。我们制定了一份关于布罗达单抗治疗中重度银屑病的德尔菲共识文件。基于已发表的文献及其临床经验，一个指导委员会起草了17项声明，涵盖了使用布罗达单抗治疗中重度银屑病所特有的7个领域。一个由32名意大利皮肤科医生组成的小组使用在线改良德尔菲法，采用5级李克特量表（从1 =“强烈不同意”到5 =“强烈同意”）表明他们的同意程度。在第一轮投票（32名参与者）后，17项提议声明中的15项（88.2%）达成了积极共识。在一次面对面的虚拟会议之后，指导委员会决定5项声明将构成“主要原则”，10项声明构成最终清单。在第二轮投票后，5项主要原则中的4项（80%）以及共识声明中的8项（80%）达成了共识。5项主要原则和10项共识声明的最终清单确定了布罗达单抗在意大利治疗中重度银屑病的特定关键适应症。这些声明有助于皮肤科医生管理中重度银屑病患者。
